This site is intended for healthcare professionals
Guidelines
  • Home
  • /
  • Guidelines
  • /
  • Coagulation and haemorrhagic disorders
  • /
  • Diagnosis and treatment of factor VIII and IX inhi...
Guideline

Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)

Read time: 1 mins
Last updated:14th Nov 2012
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition) - United Kingdom Haemophilia Centre Doctors' Organization (UKHCDO)


This document updates UK Haemophilia Centre Doctors Organization (UKHCDO) guidelines on the management of factor VIII/IX (FVIII/IX) inhibitors in congenital haemophilia (Hay et al, 2000, 2006). Acquired haemophilia is excluded and will be covered separately. Most data apply to FVIII inhibitors and the recommendations for FIX inhibitors are sometimes extrapolated from this. Low titre inhibitors are defined as <5 Bethesda units (BU)/ml and high titre 5 ≥ BU/ml. These guidelines are targeted towards haemophilia treaters in the UK. Not all recommendations may be appropriate for other countries with different health care arrangements and resources.

 

Read full guideline